Posted by Michael Wonder on 08 Mar 2024
Boehringer Ingelheim caps patient out of pocket costs for its inhaler portfolio at $35 per month
7 March 2024 - Boehringer makes significant investment to improve the affordability of and access to its full range of inhaler products for COPD and asthma.
Boehringer Ingelheim today announced it will cap out-of-pocket costs at $35 per month for eligible patients for all the company's inhaler products.
